目的探讨孟鲁司特联合沙美特罗替卡松气雾剂治疗咳嗽变异性哮喘(CVA)患者的临床效果。方法选取2014年1-12月沈阳市第五人民医院收治的84例CVA患者作为研究对象,按随机数字表法将其分为观察组和对照组,各42例。对照组患者吸入沙美特罗替卡松气雾剂,观察组患者在对照组基础上睡前顿服孟鲁司特,比较两组患者的临床治疗效果、症状改善情况、治疗后复发及不良反应发生情况。结果观察组患者治疗的总有效率明显高于对照组,差异有统计学意义(P<0.05);治疗后,观察组患者的日间症状评分、夜间症状评分均明显低于对照组,差异均有统计学意义(均P<0.05);观察组患者的复发率明显低于对照组,差异有统计学意义(P<0.05)。结论孟鲁司特联合沙美特罗替卡松气雾剂治疗CVA能明显缓解患者的临床症状,且复发率低,不良反应少。 Objective To investigate the clinical effect of montelukast combined with salmeterol and fluticasone aerosol in the treatment of patients with cough variant asthma (CVA). Methods Eighty-four patients with CVA admitted to Shenyang Fifth People’s Hospital from January to December in 2014 were selected as subjects, and divided into observation group and control group according to random number table method, with 42 cases in each group. Patients in the control group were given inhaled salmeterol and fluticasone aerosol, while patients in the observation group were treated with montelukast on bedtime on the basis of the control group. The clinical effects, symptom improvement, relapse and adverse reactions after treatment were compared between the two groups What happened? Results The total effective rate of observation group was significantly higher than that of control group (P <0.05). After treatment, the scores of daytime symptom scores and nighttime symptoms in observation group were significantly lower than those in control group (P <0.05). The recurrence rate of the observation group was significantly lower than that of the control group, the difference was statistically significant (P <0.05). Conclusion Montelukast combined with salmeterol and fluticasone aerosol can significantly relieve the clinical symptoms of patients with CVA, and the recurrence rate is low with fewer adverse reactions.